|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
Swedish biotech company Immunicum has begun to rally before the MERECA Phase II metastatic RCC study results which will be presented in the first week of September this year. But the stock is still very cheap in my view with respect to its risk/reward. tinyurl.com
My thorough analysis of Immunicum's MERECA study outlook automatically translated to English from the Swedish original seems readable even without to much editing :
It explains why for examle I have a big share of Immunicum in my portfolio and look forward to the results of MERECA in the first week of September. There is also a link to a Immunicum presentation for those who want to learn more how ilixadencel is positioned in the cancer immunotherapy landscape as a so called primer (of tumorspecific CD8+ cytotoxic T-cells) with enormous potential in all injectable solid tumors.
|© 2021 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|